Inhibition of hepatitis C virus translation and subgenomic replication by siRNAs directed against highly conserved HCV sequence and cellular HCV cofactors

J Hepatol. 2005 Aug;43(2):225-34. doi: 10.1016/j.jhep.2005.02.046.

Abstract

Background/aims: Small interfering RNAs (siRNAs) are an efficient tool to specifically inhibit gene expression by RNA interference. Since hepatitis C virus (HCV) replicates in the cytoplasm of liver cells without integration into the host genome, RNA-directed antiviral strategies are likely to successfully block the HCV replication cycle. Additional benefit might arise from inhibition of cellular cofactors of HCV replication, such as proteasome alpha-subunit 7 (PSMA7) or Hu antigen R (HuR).

Methods: In this study, we investigated direct and cofactor-mediated inhibition of HCV by a panel of DNA-based retroviral vectors expressing siRNAs against highly conserved HCV sequences or the putative HCV cofactors PSMA7 and HuR. Effects were determined in HCV IRES-mediated translation assays and subgenomic HCV replicon cells.

Results: PSMA7- and HuR-directed siRNAs successfully inhibited expression of the endogenous genes, and PSMA7 and HuR silencing significantly diminished HCV replicon RNA and NS5B protein levels. HCV-directed siRNAs substantially inhibited HCV IRES-mediated translation and subgenomic HCV replication. Combinations of PSMA7- and HuR-directed siRNAs with HCV-directed siRNAs revealed additive HCV RNA inhibitory effects in monocistronic replicon cells.

Conclusions: A dual approach of direct- and cofactor-mediated inhibition of HCV replication might avoid selection of mutants and thereby become a powerful strategy against HCV.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, Surface / metabolism
  • Blotting, Northern
  • Blotting, Western
  • Cysteine Endopeptidases / drug effects*
  • Cysteine Endopeptidases / metabolism
  • ELAV Proteins
  • ELAV-Like Protein 1
  • Gene Expression Regulation, Viral / drug effects
  • Genes, Viral / drug effects
  • Genome, Viral
  • Hepacivirus / drug effects
  • Hepacivirus / physiology*
  • Humans
  • In Vitro Techniques
  • Liver / cytology
  • Liver / metabolism
  • Liver / virology
  • Plasmids
  • Proteasome Endopeptidase Complex
  • Protein Biosynthesis / drug effects*
  • Protein Subunits / antagonists & inhibitors*
  • Protein Subunits / metabolism
  • RNA, Small Interfering / pharmacology*
  • RNA, Viral / antagonists & inhibitors
  • RNA, Viral / genetics
  • RNA-Binding Proteins / antagonists & inhibitors*
  • RNA-Binding Proteins / metabolism
  • Transfection
  • Viral Nonstructural Proteins / antagonists & inhibitors
  • Viral Nonstructural Proteins / metabolism
  • Viral Structural Proteins / genetics
  • Virus Replication / drug effects*
  • Virus Replication / genetics

Substances

  • Antigens, Surface
  • ELAV Proteins
  • ELAV-Like Protein 1
  • ELAVL1 protein, human
  • Protein Subunits
  • RNA, Small Interfering
  • RNA, Viral
  • RNA-Binding Proteins
  • Viral Nonstructural Proteins
  • Viral Structural Proteins
  • NS-5 protein, hepatitis C virus
  • Cysteine Endopeptidases
  • PSMA7 protein, human
  • Proteasome Endopeptidase Complex